Twist Bioscience (TWST) Free Cash Flow (2017 - 2026)

Twist Bioscience has disclosed Free Cash Flow across 10 years of filings, most recently posting -$13.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 7.77% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$87.8 million (down 45.35% YoY), while the FY2025 annual figure was -$75.6 million, down 9.34% from the prior year.
• Free Cash Flow climbed to -$13.1 million in Q1 2026, from -$34.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for TWST reached as high as $3.9 million in Q3 2023 and fell as low as -$74.8 million in Q2 2022.
• The 5-year median for Free Cash Flow is -$23.6 million (2024), against an average of -$29.6 million.
• Annual changes were most pronounced in 2023 — Free Cash Flow soared 122.05% — and 2024, when it slumped 543.02%.
• A 5-year view of Free Cash Flow shows it stood at -$65.9 million in 2022, then jumped by 62.85% to -$24.5 million in 2023, then advanced by 3.74% to -$23.6 million in 2024, then plunged by 47.63% to -$34.8 million in 2025, then jumped by 62.27% to -$13.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$13.1 million, -$34.8 million, and -$24.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.